{
  "docId": "019de075-e64c-773b-a5bd-08e51f7033a7",
  "docSlug": "8122e3ca3ef658190e4851ff70e19f61",
  "documentTitle": "Arbutus Biopharma | Investor Presentation Deck | 25 slides",
  "authorId": "arbutus-biopharma",
  "authorName": "Arbutus Biopharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 16,
  "pageCount": 25,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "appendix_data",
  "function": "summarize",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a bulleted list to present key safety outcomes, including lack of serious adverse events and stability of laboratory markers.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-e64c-773b-a5bd-08e51f7033a7/16",
  "deckHref": "/decks/019de075-e64c-773b-a5bd-08e51f7033a7",
  "deckJsonHref": "/decks/019de075-e64c-773b-a5bd-08e51f7033a7.json",
  "deckAnchorHref": "/decks/019de075-e64c-773b-a5bd-08e51f7033a7#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.605,
        "w": 0.805,
        "x": 0.076,
        "y": 0.235
      },
      "kind": "list",
      "text": "Imdusiran is generally safe and well-tolerated after repeat dosing for up to 48 weeks\nNo treatment-related SAEs or discontinuations due to AEs\nNo treatment-related Grade 3 or 4 AEs\nNo treatment-related Grade 3 or 4 laboratory abnormalities\nGrade 1 and Grade 2 ALT elevations have improved or stabilized with continued treatment\nInjection site AEs were all Grade 1 (erythema, pain, bruising)\nNo clinically meaningful changes in ECGs or vital signs\nAfter NA treatment discontinuation, no ALT flares have been observed",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b56ddfeb-90db-4b82-abbe-1519d231391f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.025,
        "w": 0.243,
        "x": 0.144,
        "y": 0.948
      },
      "kind": "source-note",
      "text": "SAE: Serious Adverse Event | AE: Adverse Event",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "768658ab-636e-415a-95ea-c4fc784e3722",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.118,
        "w": 0.498,
        "x": 0.076,
        "y": 0.065
      },
      "kind": "title",
      "text": "AB-729-001 Safety Summary",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2d2c0dda-d3dd-4cb8-8465-95cc4207b9fc",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}